Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Vaccine

• Publication date

  1988-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0264-410X(88)90140-5PMID 2848377
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthetic peptides: a next generation of vaccines?

  1987cited by this paper
• The immunology of new generation vaccines.

  1987cited by this paper
• Reinfection with influenza A (H2N2, H3N2, and H1N1) viruses in soldiers and students in Japan.

  1986cited by this paper
• Cyclic Nucleotides: Mediators of Bacterial Toxin Action in Disease

  1984cited by this paper
• Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin.

  1984cited by this paper
• A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions.

  1984cited by this paper
• Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen.

  1984cited by this paper
• IgA isotype restriction in the mucosal but not in the extramucosal immune response after oral immunizations with cholera toxin or cholera B subunit.

  1983cited by this paper
• Cholera and the immune response.

  1983cited by this paper
• Actions of cholera toxin and the prevention and treatment of cholera

  1981cited by this paper
• Special features of the priming process for a secretory IgA response. B cell priming with cholera toxin

  1981cited by this paper
• An improved processing of radioimmunoassay data by means of a desk-top calculator

  1979cited by this paper
• The role of antigen form and function in the primary and secondary intestinal immune responses to cholera toxin and toxoid in rats

  1978cited by this paper
• An improved processing of radioimmunoassay data by means of a desk-top calculator. (1) Comparison of regression procedures applied to selected kinds of radioimmunoassay.

  1977cited by this paper
• Regulation of the in vitro early anamnestic antibody response by exogenous cholera enterotoxin and cyclic AMP.

  1975cited by this paper
• Modulation of in vivo antibody responses by cholera toxin.

  1975cited by this paper
• Lymphocyte depletion induced by cholera toxin; relationship to adrenal cortical function.

  1975cited by this paper
• INTERACTION OF CHOLERA TOXIN AND TOXIN DERIVATIVES WITH LYMPHOCYTES

  1974cited by this paper
• Specific binding of cholera toxin to isolated intestinal microvillous membranes.

  1974cited by this paper
• Gangliosides as membrane receptors for tetanus toxin, cholera toxin and serotonin

  1974cited by this paper
• Immunity to infections on secretory surfaces.

  1974cited by this paper
• Localization of cholera toxin in vivo.

  1972cited by this paper
• Standardized viral hemagglutination and hemagglutination-inhibition tests. I. Standardization of erythrocyte suspensions.

  1969cited by this paper
• A Permeability Factor (Toxin) Found in Cholera Stools and Culture Filtrates and its Neutralization by Convalescent Cholera Sera

  1965cited by this paper
• COMPARISONS OF SEROLOGIC AND FEBRILE RESPONSES IN HUMANS TO VACCINATION WITH INFLUENZA A VIRUSES OR THEIR HEMAGGLUTININS.

  1964cited by this paper

• Correlations Between Rheology, In Situ Mucosal Retention and In Vivo Immunogenicity Reveal the Potential and Limitations of Mucoadhesive Excipients for Sublingual Vaccine Delivery

  2025cites this paper
• Effect of cigarette smoke on mucosal vaccine response with activation of plasmacytoid dendritic cells: The outcomes of in vivo and in vitro experiments.

  2023cites this paper
• Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology

  2022cites this paper
• Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza

  2021cites this paper
• Induction of mucosal immunity by pulmonary administration of a cell-targeting nanoparticle

  2021cites this paper
• Fusion-expressed CtxB-TcpA-C-CPE improves both systemic and mucosal humoral and T-cell responses against cholera in mice.

  2021cites this paper
• Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights

  2021cites this paper
• Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus

  2020cites this paper
• Nasal Influenza Vaccines

  2020cites this paper
• Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice

  2020influential citation
• Biochemical and immunological characterization of an ETEC CFA/I adhesin cholera toxin B subunit chimera

  2020cites this paper
• CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses.

  2019cites this paper
• The Potential of a Commercial Product based on Bacillus thuringiensis Cry1A-Cry2A Toxins as an Immunogen and Adjuvant

  2018cites this paper
• Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides

  2018influential citation
• Mucosal Immune Response in Nasal-Associated Lymphoid Tissue upon Intranasal Administration by Adjuvants

  2018cites this paper
• Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics

  2018cites this paper
• Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus.

  2017cites this paper
• Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate

  2017cites this paper
• Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?

  2016cites this paper
• Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus

  2016cites this paper
• Conserved hemagglutinin peptides of influenza virus as potential multivalent vaccine candidate: characterization of immune response in different animal models

  2016cites this paper
• CpG Oligodeoxynucleotides Facilitate Delivery of Whole Inactivated H9N2 Influenza Virus via Transepithelial Dendrites of Dendritic Cells in Nasal Mucosa

  2015cites this paper
• Comparison of the Mucosal Adjuvant Endocine™ with Two Well-Known Adjuvants: Cholera Toxin and Alum

  2015cites this paper
• Cross-reactivity of immunoglobulin A secreted on the nasal mucosa in mice nasally inoculated with inactivated H1N1 influenza A viruses in the presence of D-octaarginine-linked polymers.

  2015cites this paper
• [Study of next generation influenza vaccine focused on "cross-protection by mucosal immunization" and "seed virus strains"].

  2013cites this paper
• Targeting the Highly Conserved Sequences in Influenza A Virus

  2013cites this paper
• This information is current as and Ig-Binding Activity Dependent on the ADP-Ribosyltransferase Gene Fusion Protein, CTA1-DD, Is Critically Adjuvanticity of the Cholera Toxin A1-Based

  2013cites this paper
• Effect of intranasal immunization with inactivated avian influenza virus on local and systemic immune responses in ducks.

  2012cites this paper
• The mucosal vaccine quandary: Intranasal vs. sublingual immunization against influenza

  2012cites this paper
• Induction of mucosal and systemic antibody and T-cell responses following prime–boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations

  2011cites this paper
• Cross-protective immunity against influenza virus infections induced by intranasal vaccination together with a TLR3-mucosal adjuvant

  2011cites this paper
• El sueño de Elie Metchnikoff: evaluación funcional de nuevas cepas de probióticos

  2011cites this paper
• Immune response to intranasal and intraperitoneal immunization with Kaposi's sarcoma-associated herpesvirus in mice.

  2010cites this paper
• Molecular basis of the mucosal immune system: from fundamental concepts to advances in liposome-based vaccines.

  2010cites this paper
• The influence of liposomal adjuvant on intranasal vaccination of chickens against Newcastle disease.

  2010cites this paper
• Development of intranasal influenza vaccine

  2010cites this paper
• mouse ) in nasal wash in nasal wash 0 IO 20 30 40 50 0 1 2 3 4 5 L JgA 口 19

  2010cites this paper
• Studies on the usefulness of intranasal inactivated influenza vaccines.

  2010cites this paper
• Trends in development of the influenza vaccine with broader cross-protection.

  2010cites this paper
• Cloning and expression of a cholera toxin beta subunit in Escherichia coli

  2010cites this paper
• PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens

  2010cites this paper
• Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments.

  2010cites this paper
• An evaluation of the anti-inflammatory, antipyretic and antinociceptive effects of Ficus exasperata (Vahl) leaf extract.

  2009cites this paper
• Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge

  2009cites this paper
• Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.

  2009cites this paper
• Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract.

  2009cites this paper
• Cytokine-bearing Influenza Vaccine: Adjuvant Potential of Membrane-bound Immunomodulators

  2009influential citation
• Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy.

  2009cites this paper
• Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant.

  2008cites this paper
• Mouse models for the study of mucosal vaccination against otitis media.

  2008cites this paper
• Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin

  2008cites this paper
• Controlled expression of cholera toxin B subunit from Vibrio cholerae in Escherichia coli.

  2008cites this paper
• Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin.

  2008cites this paper
• Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice

  2008cites this paper
• Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by Type I and Type II heat-labile enterotoxins

  2007cites this paper
• The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response

  2007cites this paper
• Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic

  2007cites this paper
• Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza Virus (cid:1)

  2007cites this paper
• Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza Virus

  2007cites this paper
• Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.

  2007cites this paper
• Comparison of the pathogenesis and immune responses following avian Metapneumovirus subtype A and B infection in broiler-type chickens

  2007cites this paper
• Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination.

  2007cites this paper
• Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model.

  2007cites this paper
• Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant

  2006cites this paper
• Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.

  2005cites this paper
• Induction of protective antibody responses against pseudorabies virus by intranasal vaccination with glycoprotein B in mice

  2005cites this paper
• Chapter 54 – Mucosal Adjuvants

  2005cites this paper
• Macrophage inflammatory protein‐1α expression plasmid enhances DNA vaccine‐induced immune responses against HSV‐2

  2005cites this paper
• Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection

  2005cites this paper
• Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant

  2005cites this paper
• Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.

  2004cites this paper
• Efecto de la protoxina Cry1A(c) de Bacillus thuringiensis sobre células inmunocompetentes y su implicación en mecanismos de inmunogenicidad y adyuvanticidad

  2004cites this paper
• Defense mechanisms against influenza virus infection in the respiratory tract mucosa.

  2004cites this paper
• Secretory IgA antibodies provide cross‐protection against infection with different strains of influenza B virus

  2004cites this paper
• Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1.

  2004cites this paper
• Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.

  2004cites this paper
• Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia.

  2003cites this paper
• Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin.

  2003cites this paper
• Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

  2003cites this paper
• B- and T-cell responses to the mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues. Role of adjuvants and routes of immunization.

  2003cites this paper
• Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus.

  2003cites this paper
• Les chitosanes – nouveaux adjuvants pour la vaccination par voie muqueuse chez les animaux

  2003cites this paper
• Protection Against Influenza Virus Infection in Polymeric Ig Receptor Knockout Mice Immunized Intranasally with Adjuvant-Combined Vaccines

  2002cites this paper
• Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine.

  2002cites this paper
• Synthesis of cholera toxin B subunit gene: cloning and expression of a functional 6XHis-tagged protein in Escherichia coli.

  2002cites this paper
• Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.

  2002cites this paper
• Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K).

  2002cites this paper
• Oral Administration of Recombinant Cholera Toxin Subunit B Inhibits IL-12-Mediated Murine Experimental (Trinitrobenzene Sulfonic Acid) Colitis1

  2001influential citation
• Immunogenicity and protection in mice given inactivated influenza vaccine, MPL, QS-21 or QS-7

  2001cites this paper
• Identification et caractérisation de protéines immunogènes chez Chlamydophila (Chlamydia) pneumoniae

  2001cites this paper
• Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti‐influenza vaccine *

  2001cites this paper
• Murine Experimental (Trinitrobenzene Toxin Subunit B Inhibits IL-12-Mediated Oral Administration of Recombinant Cholera

  2001influential citation
• Intranasal Immunization with Recombinant Ascaris suum14-Kilodalton Antigen Coupled with Cholera Toxin B Subunit Induces Protective Immunity to A. suum Infection in Mice

  2001cites this paper
• Polymeric lamellar substrate particles for intranasal vaccination.

  2001cites this paper
• Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine.

  2001cites this paper
• Kinetics and type of immune response following intranasal and subcutaneous immunisation of calves.

  2001cites this paper
• Mucosal vaccination against influenza: protection of pigs immunized with inactivated virus and ether-split vaccine.

  2001cites this paper
• Cytokine mRNAs in the nasal-associated lymphoid tissue during influenza virus infection and nasal vaccination.

  2000cites this paper
• Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract.

  2000cites this paper
• Carbohydrate Biopolymers Enhance Antibody Responses to Mucosally Delivered Vaccine Antigens

  2000cites this paper